At the forefront of the field of psychedelic-assisted therapy, InnerMost is conducting a number of industry-sponsored and independently initiated clinical trials. Building on his 15 years of experience in psychedelic-assisted therapy research, Dr. Casey Paleos guides our research team as Principal Investigator in all current and future trials.
Research into CYB003, a next-generation psilocybin analog, is showing meaningful improvements for some individuals living with depression. This study offers an opportunity to explore how such treatment might support healing for those living with depression.
This is a long-term extension study that allows for open-label dosing or re-dosing—for participants who did not respond in the first two studies, or relapsed during the extension study. Participants will need to complete either of the first two CYB003 for MDD trials to participate.
Frontline healthcare workers endured extraordinary stress during the pandemic, and many continue to carry symptoms of trauma. This study seeks to explore whether MDMA-assisted therapy can provide meaningful relief and support for those who served in these critical roles.
Explore our services in psychedelic-assisted therapy, clinical research, and therapist training—designed to support your healing journey.
Explore common questions about participation in one of our research trials.
